Generic Pharmaceuticals Market Share Analysis Report, 2023-2032
The global generic pharmaceuticals market size was exhibited at USD 362.9 billion in 2022 and is projected to hit around USD 812.98 billion by 2032, growing at a CAGR of 8.4% during the forecast period 2023 to 2032.
Key Pointers:
Generic Pharmaceuticals Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 393.38 Billion |
|
Market Size by 2032 |
USD 812.98 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 8.4% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Type, Application, Product, Route of administration, Distribution channel |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
Teva Pharmaceutical Industries Ltd.; Viatris Inc. Novartis AG; Sun Pharmaceutical Industries Ltd.; LUPIN, AbbVie Inc. (Allergan); AstraZeneca; Sawai Pharmaceutical Co., Ltd.; Hikma Pharmaceuticals PLC; Dr. Reddy’s Laboratories Ltd.; Cipla Inc.; Sanofi; Aurobindo Pharma; Endo International plc. |
The growth of the generic pharmaceuticals market is largely attributable to the expiry of product patents which clears the way for generic drugs and biosimilar manufacturers to launch products in the market. For instance, in July 2020, Teva Pharmaceutical Industries Ltd. entered into a joint venture with Takeda Pharmaceutical Company Limited aimed to manufacture and commercialize specialty assets, complex generic drugs, and other pipeline opportunities. This joint venture was anticipated to drive the generic pharmaceuticals market.
Furthermore, increasing government initiatives to promote generic drug products for reducing the overall healthcare expenditure on pharmaceuticals and the patent expiry of major products. For instance, the Therapeutic Goods Administration (TGA) Australia aims to offer affordable, efficient, high-quality, and accessible generic drugs to citizens for their treatment. In support of generic drugs, the TGA has been trying to reduce regulatory and reimbursement burdens such as changing the landscape of generic drugs and reducing barriers through international collaboration with manufacturers to launch their generic drugs in the market. Such initiatives of the Australian government open new avenues in the market.
In the U.S., every year millions of Americans use a generic drug for their treatment, hence, generic drugs remain the best bargain in the health care insurance programs, and given the recent enactment of healthcare reform legislation such as the introduction of the Patient Protection and Affordable Health Care Act. P.L. 111-148. Under this act, prescription drug coverage is mandated by the government as part of these new health insurance plans. The introduction of such policies may improve the quality and efficiency of healthcare, thereby, driving market growth.
The rising disease burden of infectious & non-infectious diseases coupled with the increasing geriatric population which is prone to chronic diseases such as diabetes, and hypertension, among others, may positively affect the market growth. According to an article published, in September 2022, around 17.9 million general population suffer from cardiovascular diseases (CVD) every year worldwide. Diseases including TB, diabetes, cardiovascular diseases, and HIV were among the major causes of death. The increasing incidence and prevalence of these diseases is expected to drive the market.
Some of the prominent players in the Generic Pharmaceuticals Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Generic Pharmaceuticals market.
By Type
By Application
By Product
By Route of Administration
By Distribution Channel
By Region
Chapter 1 Methodology and Scope
1.1 Market segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Primary Research Analysis
1.11.1 Market scenario
1.11.2 Key KoL responses
1.12 Objectives
1.12.1 Objective 1:
1.12.2 Objective 2:
1.13 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Snapshoty
Chapter 3 Market Variables, Trends & Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory Landscape
3.3 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.4 Porter’s Five Forces Analysis
3.5 User Perspective Analysis
3.6 Generic Pharmaceuticals Market Dynamics
3.6.1 Market Driver Analysis
3.6.1.1 Patent expiry of biologics and small molecules
3.6.1.2 Increasing ANDA approval and Generic Product Launches
3.6.1.3 Government initiatives to promote usage of generics
3.6.1.4 Increasing Disease Burden and Rising Geriatric Population
3.6.2 Market Restraint Analysis
3.6.2.1 Pricing Pressures
Chapter 4 Generic Pharmaceuticals Market - Segment Analysis, By Type, 2020 - 2032
4.1 Generic Pharmaceuticals Market: Type Movement Analysis
4.2 Simple Generics
4.2.1 Simple Generics Market Estimates and Forecast, 2020 - 2032
4.3 Specialty Generics
4.3.1 Specialty Generics Market Estimates and Forecasts, 2020 - 2032
4.4 Biosimilars
4.4.1 Biosimilars Market Estimates and Forecasts, 2020 - 2032
Chapter 5 Generic Pharmaceuticals Market - Segment Analysis, By Application, 2020 - 2032
5.1 Generic Pharmaceuticals Market: Application Movement Analysis
5.2 Central Nervous System Disorders
5.2.1 Central Nervous System Disorders Market Estimates and Forecast, 2020 - 2032
5.3 Respiratory Diseases
5.3.1 Respiratory Diseases Market Estimates and Forecast, 2020 - 2032
5.4 Hormones and Related Diseases
5.4.1 Hormones and Related Diseases Market Estimates and Forecast, 2020 - 2032
5.5 Gastrointestinal Diseases
5.5.1 Gastrointestinal Diseases Market Estimates and Forecast, 2020 - 2032
5.6 Cardiovascular Diseases
5.6.1 Cardiovascular Diseases Market Estimates and Forecast, 2020 - 2032
5.7 Infectious Diseases
5.7.1 Infectious Diseases Market Estimates and Forecast, 2020 - 2032
5.8 Cancer
5.8.1 Cancer Market Estimates and Forecast, 2020 - 2032
5.9 Diabetes
5.9.1 Diabetes Market Estimates and Forecast, 2020 - 2032
5.10 Others
5.10.1 Others Market Estimates and Forecast, 2020 - 2032
Chapter 6 Generic Pharmaceuticals Market - Segment Analysis, By Product, 2020 - 2032
6.1 Generic Pharmaceuticals Market: Product Movement Analysis
6.2 Small Molecule
6.2.1 Small Molecule Market Estimates and Forecasts, 2020 - 2032
6.3 Large Molecule
6.3.1 Large molecule Market Estimates and Forecasts, 2020 - 2032
Chapter 7 Generic Pharmaceuticals Market - Segment Analysis, By Route of Administration, 2020 - 2032
7.1 Generic Pharmaceuticals Market: Route of Administration Movement Analysis
7.2 Oral
7.2.1 Oral Market Estimates and Forecast, 2020 - 2032
7.3 Injectable
7.3.1 Injectable Market Estimates and Forecast, 2020 - 2032
7.4 Inhalable
7.4.1 Inhalable Market Estimates and Forecast, 2020 - 2032
7.5 Others
7.5.1 Others Market Estimates and Forecast, 2020 - 2032
Chapter 8 Generic Pharmaceuticals Market - Segment Analysis, By Distribution Channel, 2020 - 2032
8.1 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
8.2 Hospital Pharmacy
8.2.1 Hospital Pharmacy Market Estimates and Forecast, 2020 - 2032
8.3 Retail Pharmacy
8.3.1 Retail Pharmacy Market Estimates and Forecast, 2020 - 2032
8.4 Online Pharmacy
8.4.1 Online Pharmacy Market Estimates and Forecast, 2020 - 2032
Chapter 9 Generic Pharmaceuticals Market - Segment Analysis, By Region, 2020 - 2032
9.1 Generic Pharmaceuticals Market, Market Share by Region, 2022 & 2032
9.2 North America
9.2.1 SWOT Analysis
9.2.1.1 North America Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 U.S. Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 Canada Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2 Europe
9.2.1 SWOT Analysis:
9.2.1.1 Europe Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.2 Germany
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 Germany Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.3 U.K.
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 UK Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.4 France
9.2.4.1 Key Country Dynamics
9.2.4.2 Target Disease Prevalence
9.2.4.3 Competitive Scenario
9.2.4.4 Regulatory Framework
9.2.4.5 Reimbursement Scenario
9.2.4.6 France Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.5 Italy
9.2.5.1 Key Country Dynamics
9.2.5.2 Target Disease Prevalence
9.2.5.3 Competitive Scenario
9.2.5.4 Regulatory Framework
9.2.5.5 Reimbursement Scenario
9.2.5.6 Italy Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.6 Spain
9.2.6.1 Key Country Dynamics
9.2.6.2 Target Disease Prevalence
9.2.6.3 Competitive Scenario
9.2.6.4 Regulatory Framework
9.2.6.5 Reimbursement Scenario
9.2.6.6 Spain Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.7 Denmark
9.2.7.1 Key Country Dynamics
9.2.7.2 Target Disease Prevalence
9.2.7.3 Competitive Scenario
9.2.7.4 Regulatory Framework
9.2.7.5 Reimbursement Scenario
9.2.7.6 Denmark Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.8 Sweden
9.2.8.1 Key Country Dynamics
9.2.8.2 Target Disease Prevalence
9.2.8.3 Competitive Scenario
9.2.8.4 Regulatory Framework
9.2.8.5 Reimbursement Scenario
9.2.8.6 Sweden Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.9 Norway
9.2.9.1 Key Country Dynamics
9.2.9.2 Target Disease Prevalence
9.2.9.3 Competitive Scenario
9.2.9.4 Regulatory Framework
9.2.9.5 Reimbursement Scenario
9.2.9.6 Norway Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.2.9.7 Rest of Europe Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3 Asia Pacific
9.3.1 SWOT Analysis:
9.3.1.1 Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3.2 Japan
9.3.2.1 Key Country Dynamics
9.3.2.2 Target Disease Prevalence
9.3.2.3 Competitive Scenario
9.3.2.4 Regulatory Framework
9.3.2.5 Reimbursement Scenario
9.3.2.6 Japan Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3.3 China
9.3.3.1 Key Country Dynamics
9.3.3.2 Target Disease Prevalence
9.3.3.3 Competitive Scenario
9.3.3.4 Regulatory Framework
9.3.3.5 Reimbursement Scenario
9.3.3.6 China Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3.4 India
9.3.4.1 Key Country Dynamics
9.3.4.2 Target Disease Prevalence
9.3.4.3 Competitive Scenario
9.3.4.4 Regulatory Framework
9.3.4.5 Reimbursement Scenario
9.3.4.6 India Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3.5 Australia
9.3.5.1 Key Country Dynamics
9.3.5.2 Target Disease Prevalence
9.3.5.3 Competitive Scenario
9.3.5.4 Regulatory Framework & Reimbursement Scenario
9.3.5.5 Australia Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3.6 Thailand
9.3.6.1 Key Country Dynamics
9.3.6.2 Target Disease Prevalence
9.3.6.3 Competitive Scenario
9.3.6.4 Regulatory Framework & Reimbursement Scenario
9.3.6.5 Thailand Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3.7 South Korea
9.3.7.1 Key Country Dynamics
9.3.7.2 Target Disease Prevalence
9.3.7.3 Competitive Scenario
9.3.7.4 Regulatory Framework & Reimbursement Scenario
9.3.7.5 South Korea Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.3.7.6 Rest of Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.4 Latin America
9.4.1 SWOT Analysis:
9.4.1.1 Latin America Generic Pharmaceutical market estimates and forecasts, 2020 - 2032
9.4.2 Brazil
9.4.2.1 Key Country Dynamics
9.4.2.2 Target Disease Prevalence
9.4.2.3 Competitive Scenario
9.4.2.4 Regulatory Framework
9.4.2.5 Reimbursement Scenario
9.4.2.6 Brazil Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.4.3 Mexico
9.4.3.1 Key Country Dynamics
9.4.3.2 Target Disease Prevalence
9.4.3.3 Competitive Scenario
9.4.3.4 Regulatory Framework
9.4.3.5 Reimbursement Scenario
9.4.3.6 Mexico Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.4.4 Argentina
9.4.4.1 Key Country Dynamics
9.4.4.2 Target Disease Prevalence
9.4.4.3 Competitive Scenario
9.4.4.4 Regulatory Framework
9.4.4.5 Reimbursement Scenario
9.4.4.6 Argentina Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.4.4.7 Rest of Latin America Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.5 Middle East & Africa (MEA)
9.5.1 SWOT Analysis:
9.5.1.1 Middle East & Africa Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.5.2 South Africa
9.5.2.1 Key Country Dynamics
9.5.2.2 Target Disease Prevalence
9.5.2.3 Competitive Scenario
9.5.2.4 Regulatory Framework
9.5.2.5 Reimbursement Scenario
9.5.2.6 South Africa Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.5.3 Saudi Arabia
9.5.3.1 Key Country Dynamics
9.5.3.2 Target Disease Prevalence
9.5.3.3 Competitive Scenario
9.5.3.4 Regulatory Framework
9.5.3.5 Reimbursement Scenario
9.5.3.6 Saudi Arabia Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.5.4 UAE
9.5.4.1 Key Country Dynamics
9.5.4.2 Target Disease Prevalence
9.5.4.3 Competitive Scenario
9.5.4.4 Regulatory Framework
9.5.4.5 Reimbursement Scenario
9.5.4.6 UAE Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.5.5 Kuwait
9.5.5.1 Key Country Dynamics
9.5.5.2 Target Disease Prevalence
9.5.5.3 Competitive Scenario
9.5.5.4 Regulatory Framework
9.5.5.5 Reimbursement Scenario
9.5.5.6 Kuwait Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
9.5.5.7 Rest of MEA Generic Pharmaceutical Market Estimates and Forecasts, 2020 - 2032
Chapter 10 Generic Pharmaceuticals Market - Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 New Product Launch
10.1.2 Merger and Acquisition
10.1.3 Licensing Agreements
10.1.4 Conferences and Campaigns
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List of key distributors and channel partners
10.3.2 Key customers
10.4 Public Companies
10.4.1 Key company market share analysis, 2022
10.4.2 Company market position analysis
10.4.3 Heat map analysis
10.4.4 Competitive Dashboard Analysis
10.4.4.1 Market Differentiators
10.5 Private Companies
10.5.1 List of key emerging companies
10.5.2 Regional Network Map
10.6 Company Profile
10.6.1 Teva Pharmaceutical Industries Ltd
10.6.1.1 Company overview
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic initiatives
10.6.2 Viatris Inc.)
10.6.2.1 Company overview
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic initiatives
10.6.3 Sun Pharmaceutical Industries Ltd.
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic initiatives
10.6.4 LUPIN
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic initiatives
10.6.5 Novartis AG
10.6.5.1 Company overview
10.6.5.2 Sandoz International GmbH
10.6.5.3 Financial performance
10.6.5.4 Product benchmarking
10.6.5.5 Strategic initiatives
10.6.6 Allergan
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic initiatives
10.6.7 AstraZeneca
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Sawai Pharmaceutical Co., Ltd.
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Hikma Pharmaceuticals PLC
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
10.6.10 Dr. Reddy’s Laboratories Ltd.
10.6.10.1 Company overview
10.6.10.2 Financial performance
10.6.10.3 Product benchmarking
10.6.10.4 Strategic initiatives
10.6.11 Cipla Inc.
10.6.11.1 Company overview
10.6.11.2 Financial performance
10.6.11.3 Product benchmarking
10.6.11.4 Strategic initiatives
10.6.12 Sanofi
10.6.12.1 Company overview
10.6.12.2 Financial performance
10.6.12.3 Product benchmarking
10.6.12.4 Strategic initiatives
10.6.13 Aurobindo Pharma
10.6.13.1 Company overview
10.6.13.2 Financial performance
10.6.13.3 Product benchmarking
10.6.13.4 Strategic initiatives
10.6.14 Endo International plc
10.6.14.1 Company overview
10.6.14.2 Financial performance
10.6.14.3 Product benchmarking
10.6.14.4 Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers